Showing results (271-280 of 335) with videos related to

Sort By:
Pageof 34
American Journal of Hematology|July 14, 2012
The clinical spectrum of Castleman's diseaseAngela Dispenzieri, James O Armitage, Matt J Loe, et al.
Analytical and Bioanalytical Chemistry|October 17, 2016
Guilty by dissociation-development of gas chromatography-mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs)Pierre M Geyer, Matthew C Hulme, Joseph P B Irving, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 13, 2017
Imbedded Nanocrystals of CsPbBr3 in Cs4 PbBr6 : Kinetics, Enhanced Oscillator Strength, and Application in Light-Emitting DiodesJunwei Xu, Wenxiao Huang, Peiyun Li, et al.
British Journal of Haematology|February 15, 2002
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemiaD F Jelinek, R C Tschumper, S M Geyer, et al.
Leukemia & Lymphoma|December 3, 2005
A phase II trial of imatinib in patients with refractory/relapsed myelomaAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Leukemia Research|January 22, 2005
Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemiaStephanie R Fink, Sarah F Paternoster, Stephanie A Smoley, et al.
The Journal of Clinical Investigation|December 8, 2007
Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patientsRenee C Tschumper, Susan M Geyer, Megan E Campbell, et al.
Leukemia|July 31, 2020
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)Seongseok Yun, Susan M Geyer, Rami S Komrokji, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 18, 2024
Limiting Resources Define the Global Pattern of Soil Microbial Carbon Use EfficiencyYongxing Cui, Junxi Hu, Shushi Peng, et al.
Haematologica|March 1, 2006
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-pointsAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Pageof 34